Official Title
Prospective Evaluation of Antibodies Levels Variation Against SARS-CoV-2 in a Vaccinated Population of the Metropolitan Area of Valle de Aburra . Pilot Prospective Cohort.
Brief Summary

Recent research evidence shows that levels of antibodies acquierd post vacunation againstSARS-Cov-2 decrease over time as well as the efficacy to control the infection,additionally in a multicenter study carried out in 2020 were evidenced differences in thetime it took to decrease the antibodies according to the type of vaccine, defined as mRNAor other types of vaccine.In this study , the variation of the SARS-Cov-2 antibody levels in patients from Valle deAburrá will be correlated according to the COVID-19 vaccine received.

Detailed Description

After being informed about the study, all patients giving written informed consent will
undergo a serial IgM -IgG COVID-19 antibodies blood test and SARS-Cov-2 PCR by
nasopharingeal swab, that will be taken at the beginning of the study and mensually for
two months.

During the study will be done an active search for SARS-CoV-2 infections in the
vaccinated people cohort, and if it is posible to characterize the variant of SARS-CoV-2
in participants previously vaccinated against this pathogen.

The main objective of this study is to describe the pattern of antibodies blood test
based in the type of vaccine and correlated the pattern of antibodies SARS-Cov-2 levels
in a population of Valle de Aburrá.

Unknown status
COVID-19

Diagnostic Test: Levels of IgG and IgM SARS-CoV-2 antibodies blood test.

0,1,2 months

Diagnostic Test: RT-PCR SARS-CoV-2 nasopharyngeal swab

0,1,2 months

Eligibility Criteria

Inclusion Criteria:

- Adult over 18 years old

- The vaccinated patients to be included must have received a complete vaccination
scheme for COVID-19 according to the Ministerio de Salud y Protección Social de
Colombia

- SARS-CoV-2 infection in the last 2 months, verified by rtPCR test

Exclusion Criteria:

- Immunocompromised patients

- Immunosuppressive treatments, chemotherapy or antiretroviral therapy

- Outpatient anticoagulant therapy

- For vaccinated people (groups 1 and 2): if have had COVID-19 infection in the last 6
months

Eligibility Gender
All
Eligibility Age
Minimum: 18 Years ~ Maximum: 90 Years
Countries
Colombia
Locations

Laboratorio Integrado de Medicina Especializada
Medellin, Antioquia, Colombia

Investigator: Andres F Zuluaga

Contacts

Ivone Jimenez
+57 (4) 2196022
ivone.jimenez@udea.edu.co

Andres F Zuluaga, MD, MSc, MeH, Principal Investigator
Universidad de Antioquia

Universidad de Antioquia
NCT Number
Keywords
Laboratory biomarkers
Health condition
Covid-19
Antibodies level
Vaccinated people
MeSH Terms
COVID-19
Antibodies